Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Axol Bioscience Ltd. logo — Better Human Disease Models

Axol Bioscience Ltd.

Better Human Disease Models

Founded 2013 United Kingdom Cambridge, United Kingdom 49 employees Venture round Total: $10.47M Biopharma, Biotechnology

General Information

Company Name Axol Bioscience Ltd.
Founded Year 2013
Location United Kingdom Cambridge, United Kingdom
Employees 49
Industries Biopharma, Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Axol Bioscience Ltd.. To contact Axol Bioscience Ltd., visit axolbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Axol Bioscience Ltd. compare?

A PDF of Axol Bioscience Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Axol Bioscience Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Axol Bioscience Ltd.

Axol Bioscience Ltd. is a biotechnology startup based in the United Kingdom, specializing in iPSC technology to create advanced models for drug discovery. With a decade of experience, they supply human iPSC-derived cells and offer laboratory services to support drug discovery in neurodegenerative, neuroinflammatory, and cardiotoxicity areas. Their expertise in iPSC products and services has positioned them as leaders in supplying top Biopharma institutions and drug discovery companies with high-quality in vitro models and custom lab services. Their capabilities also extend to supporting advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms, demonstrating their commitment to pioneering the utility of iPSCs for research and drug discovery. At the latest funding round in April 2022, Axol Bioscience Ltd. secured a substantial £3.20M Venture Round investment from Par Equity, Scottish Enterprise, Calculus Capital, and Meltwind Advisory. This funding is expected to bolster their position as world leaders in iPSC technology and drive further innovation in creating better, safer therapies for various diseases within the biopharmaceutical and biotechnology industries.

Business keywords: iPSC technology, drug discovery, neurodegenerative diseases, neuroinflammatory diseases, cardiotoxicity, in vitro models, biopharma, organ-on-a-chip devices, microfluidics platforms, human cell culture, genome editing, iPSC reprogramming, differentiation, Cambridge, stem cell research

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round £3.20M 4
Par Equity Scottish Enterprise Calculus Capital
Par Equity, Scottish Enterprise +2
07 Apr 2022
Venture Round £3.80M 2
Par Equity Calculus Capital
Par Equity, Calculus Capital
17 Mar 2021
Venture Round £2.50M 1
Calculus Capital
Calculus Capital
16 Aug 2017
Seed Round £971.00K 3
Amadeus Capital Partners Martlet Capital
Amadeus Capital Partners, Martlet Capital +1
14 Dec 2015

Axol Bioscience Ltd. Alternatives & Competitors

Axol Bioscience Ltd. vs
CN Bio
CN Bio United Kingdom

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems.

Series B
59 employees
Biopharma, Biotechnology
Compare Axol Bioscience Ltd. vs CN Bio
Axol Bioscience Ltd. vs
OrganoTherapeutics
OrganoTherapeutics Luxembourg

Using Midbrain Organoids for the development of new Therapeutics against Parkinson`s Disease.

9 employees
Biopharma, Biotechnology
Compare Axol Bioscience Ltd. vs OrganoTherapeutics

FAQ About Axol Bioscience Ltd.

Better Human Disease Models
Axol Bioscience Ltd. was founded in 2013.
Axol Bioscience Ltd. is headquartered in Cambridge, United Kingdom.
Axol Bioscience Ltd. operates in Biopharma and Biotechnology. Its work centres on iPSC technology, drug discovery, neurodegenerative diseases and neuroinflammatory diseases.
Axol Bioscience Ltd. has approximately 49 employees.
Axol Bioscience Ltd. has completed 4 funding rounds, raising a total of $10.47M. The latest funding stage is Venture round.
Top alternatives and competitors to Axol Bioscience Ltd. include CN Bio, OrganoTherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Axol Bioscience Ltd. and CN Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Axol Bioscience Ltd., https://bouncewatch.com/company/axol-bioscience-ltd, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout